A Focus on the First 1,000 Days
Starting at conception, the health of both mother and child are of utmost importance. At Astarte Medical, we view the first 1,000 days as a window of opportunity to deliver solutions that allow hospitals and clinical teams to standardize care protocols and customize treatment plans, at a time that has a profound impact on long-term health.
These first 1,000 days are especially critical for preterm infants, who are facing significant challenges, which include:
Growth
Failure
Allergy, Asthma
and Obesity
Neurodevelopmental
Delays or Disabilities
Our NICUtrition Platform
Core to Astarte Medical is our comprehensive and proprietary dataset, which integrates feeding protocols, microbiome profiles and clinical information. Our NICUtrition® suite of products provides actionable information in real time to hospitals and clinical teams, enabling them to standardize care protocols, and customize treatment plans by quantifying preterm infant gut health.
About Astarte Medical
Led by a distinguished team and world-class advisors in neonatology, nutrition and microbiome, Astarte Medical is the only precision medicine company using software and predictive analytics to improve outcomes during the first 1,000 days of life, with an initial focus on preterm infants.
Featured News
CEO Tracy Warren discusses how gut health in the first 1000 days of life is the most critical period of growth and brain development.
Astarte medical announced $5M Series A funding round to complete its suite of digital tools and diagnostics.
Company hopes to use funding to complete development of its NICUtrition predictive analytics platform
Events
Astarte CEO, Tracy Warren, to attend event in Ann Arbor, MI.
Astarte will be exhibiting at the show in San Diego, CA.
Advancing research, understanding & application.